Serotonin receptors involved in antidepressant effects

Francesc Artigas
Department of Neurochemistry and Neuropharmacology,
Institut d’Investigacions Biomèdiques de Barcelona (IIBB-CSIC-IDIBAPS)
Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)

Running title: 5-HT receptors and antidepressants

Corresponding author: Francesc Artigas, PhD; Dept. of Neurochemistry and Neuropharmacology, IIBB-CSIC (IDIBAPS), Rosselló, 161, 6th floor, 08036 Barcelona, Spain.
Phone: +3493-363 8314; Fax: +3493-363 8301; e-mail: fapnqi@iibb.csic.es
Abstract

The neurotransmitter serotonin (5-hydroxytryptamine; 5-HT) has been implicated in the pathophysiology and treatment of major depression since the serendipitous discovery of antidepressant drugs in the 1950s. However, despite the generalised use of serotonin-enhancing drugs, such as the selective serotonin reuptake inhibitors (SSRIs) and the dual serotonin and norepinephrine reuptake inhibitors (SNRIs), the exact neurobiological mechanisms involved in the therapeutic action of these drugs are poorly understood. Better knowledge of these mechanisms may help to identify new therapeutic targets and to overcome the two main limitations of current treatments: reduced efficacy and slowness of action. Here I review the preclinical and clinical evidence supporting the involvement of different 5-HT receptors in the therapeutic action of antidepressant drugs. Presynaptic 5-HT$_{1A}$ and 5-HT$_{1B}$ autoreceptors play a major detrimental role in antidepressant treatments, as their activation by the excess of the active (extracellular) 5-HT fraction produced by serotonin transporter (SERT) blockade reduces presynaptic serotonergic function. Conversely, stimulation of postsynaptic 5-HT$_{1A}$ receptors in corticolimbic networks appears beneficial for the antidepressant action. The 5-HT$_2$ receptor family is also involved as 5-HT$_{2A/2C}$ receptor blockade improves the antidepressant action of SSRIs, and recent data suggest that 5-HT$_{2B}$ receptor activation enhances serotonergic activity. Less is known from the rest of postsynaptic 5-HT receptors. However, 5-HT$_3$ receptor blockade augments the 5-HT increase evoked by SERT inhibition, and 5-HT$_4$ receptor activation may have antidepressant effects on its own. Finally, blockade of 5-HT$_6$ and 5-HT$_7$ receptors appears also to augment the antidepressant effects of SERT inhibition.

Keywords: Antidepressant drugs; Major depression; Serotonin transporter; Serotonin receptors; SSRI; SNRI

Abbreviations

5-HIAA, 5-hydroxyindoleacetic acid
5-HT, 5-hydroxytryptamine, serotonin
BDNF, brain-derived neurotrophic factor
CREB, cyclic AMP response element-binding
CNS, central nervous system
DA, dopamine
DHPC, dorsal hippocampus

DR, dorsal raphe nucleus

GABA, \(\gamma\)-aminobutyric acid

LC; locus coeruleus

MDD, major depressive disorder

MnR, median raphe nucleus

mRNA, messenger ribonucleic acid

NE, norepinephrine

NMDA, noncompetitive N-methyl d-aspartate

PET, positron emission tomography

PFC, prefrontal cortex

REM, rapid eye movement

SERT, serotonin transporter

SNRI, serotonin and norepinephrine reuptake inhibitors

SSRI, selective serotonin reuptake inhibitors

STR, dorsal striatum

VHPC, ventral hippocampus

VTA, ventral tegmental area
Table of contents

1. Introduction

2. The serotonin system in depression

3. Serotonin receptors
   • 3.1. 5-HT$_{1A}$ receptors
   • 3.2. 5-HT$_{1B}$ receptors
   • 3.3. Other 5-HT$_{1}$ receptors
   • 3.4. 5-HT$_{2A}$ receptors
   • 3.5. 5-HT$_{2B}$ receptors
   • 3.6. 5-HT$_{2C}$ receptors
   • 3.7. 5-HT$_{3}$ receptors
   • 3.8. 5-HT$_{4}$ receptors
   • 3.9. 5-HT$_{6}$ receptors
   • 3.10. 5-HT$_{7}$ receptors

4. Conclusions and implications for new drug development
1. Introduction

Major depressive disorder (MDD) is a severe psychiatric syndrome with high prevalence and socioeconomic impact (Andlin-Sobocki et al., 2005; Smith, 2011; Kessler et al., 2005). Although it is clear that depression results from, and can result in, changes in the functional neuroanatomy of the brain (Sheline et al., 1996; Duman et al., 1997; Drevets et al., 2008; Seminowicz et al., 2004), the underlying pathophysiology of MDD has not yet been clearly defined. Numerous clinical and preclinical studies indicate that a disturbance in central serotonin (5-hydroxytryptamine; 5-HT) activity is a key factor; however, other monoaminergic neurotransmitters (e.g. norepinephrine -NE- and dopamine -DA-) have also been implicated (Harro and Oreland, 2001; Nestler et al., 2002; Nestler and Carlezon, 2006). More recently, glutamatergic neurotransmission has been implicated, based on the observation that ketamine (noncompetitive N-methyl d-aspartate -NMDA- receptor antagonist) shows rapid and persistent antidepressant effects (Zarate et al., 2006).

Despite the large body of research focusing on the mechanisms underlying antidepressant efficacy (Blier and de Montigny, 1994; Artigas et al., 1996; Celada et al., 2004; Berton and Nestler, 2006), current antidepressants remain limited – especially in terms of onset of action and overall efficacy (Trivedi et al., 2006; Rush et al., 2006; Rush et al, 2011). The aim of this article is to review our current knowledge of the role of the serotonergic system in depression, including the many serotonergic receptors identified, and how targeting these receptors in novel ways may lead to the development of new antidepressants.

2. The serotonin system in depression

Abnormalities in serotonergic function have been believed to be a common factor in several related mental illnesses since the 1950s (Woolley and Shaw, 1954). Since then, the link
between serotonin and depression has been further clarified by clinical studies that have shown that an acute, transient relapse of depressive symptoms can be produced in subjects in remission using the irreversible 5-HT synthesis inhibitor p-chlorophenylalanine (Shopsin et al., 1975; Shopsin et al., 1976) or tryptophan depletion (Delgado et al., 1990; Price et al., 1990) to cause a temporary reduction in central serotonin levels. Overall, these studies show that clinical efficacy of antidepressant drugs depends on presynaptic serotonergic function. Similarly, other studies have shown reduced cerebrospinal fluid concentrations of the serotonin major metabolite – 5-hydroxyindoleacetic acid (5-HIAA) – in drug-free depressed patients (Asberg et al., 1976, Roy et al., 1989) as well as reduced concentrations of 5-HT and its main metabolite (5-HIAA) in the postmortem brain tissue of depressed and/or suicidal patients.

Perhaps the strongest evidence for the role of the serotonergic system in MDD is the efficacy of antidepressants that target the serotonin transporter (SERT) – namely, the selective serotonin reuptake inhibitors (SSRIs) and the dual serotonin and norepinephrine reuptake inhibitors (SNRIs) – which account for more than 90% of the global antidepressant market. A full review of the serotonergic system is beyond the scope of the present article but has been well covered in other comprehensive reviews (Azmitia and Whitaker-Azmitia, 1991; Jacobs and Azmitia, 1992; Smythies, 2005). However, before focusing on the numerous 5-HT receptors, it is important to understand the basic characteristics of the serotonergic system relevant to understanding the effects of antidepressant therapy (Box 1).

First, the serotonergic neurons of the mammalian brain comprise the most extensive and complex neurochemical network in the central nervous system (CNS) after that of glutamate, which makes up the basic wiring of the brain. It has been estimated that the human brain contains about 250 000 5-HT neurons of a total of $10^{11}$ neurons (Jacobs and Azmitia, 1992). Importantly, whereas serotonergic neurons originate mainly in the brainstem dorsal and median
raphe nuclei, their axons arborise over large areas such that they innervate almost every area of
the brain with high densities of axonal varicosities. Hence, densities of >10⁶ nerve
terminals/mm³ have been reported in rat neocortex (Beaudet and Descarries, 1976).

Second, whereas some serotonergic projections form classical chemical synapses, many do
not, but instead release 5-HT in a paracrine manner (sometimes termed ‘volume transmission’).
Thirdly, serotonin neurons are tonically active with a slow (~1 Hz) and regular activity that
ceases during rapid eye movement sleep (REM-off neurons), in parallel with noradrenergic
neurons of the locus coeruleus (Smythies, 2005). Finally, it is also important to understand that
under normal conditions, the activity of serotonergic neurons is tightly controlled via a number of
mechanisms including – among others – glutamatergic inputs from forebrain areas such as the
prefrontal cortex (Celada et al., 2001; Fink et al., 1995; Martin-Ruiz et al., 2001a), tonic
noradrenergic input from the pontine nuclei (Peyron et al., 1996; O’Leary et al., 2007;
VanderMaelen and Aghajanian, 1983), inhibitory γ-aminobutyric acid (GABA)-ergic inputs from
local interneurons (Bagdy et al., 2000; Gervasoni et al., 2000; Varga et al., 2001) and
dopaminergic input from the midbrain dopaminergic nuclei (Martin-Ruiz et al., 2001b). In
addition, the serotonin system is involved in ‘self-regulation’ of serotonergic activity. Indeed, a
key control mechanism of 5-HT neurons is self-inhibition through 5-HT₁A autoreceptors, which
will be discussed in detail later. Taken together, these basic anatomical and electrophysiological
characteristics mean that changes in the activity of serotonergic neurons influence a large
population of target neurons in the forebrain.

Considering the complex nature of the serotonergic system and the interplay with other
neurochemical systems, numerous mechanisms may play a role in MDD development.
Currently, mechanisms suggested include low neuronal production of serotonin or of
postsynaptic receptors, reduced excitatory inputs or excessive self-inhibition, reduced 5-HT
synthesis and/or tryptophan shortage. Regardless of the exact mechanisms, depression is attributable, at least in part, to abnormal transmission at central 5-HT synapses; therefore, agents that modulate serotonergic transmission in the brain are predicted to be effective antidepressants.

3. 5-HT receptors

Following SSRI development, serotonergic targets other than SERT – namely, the 5-HT receptors – have received much research attention. Serotonin mediates its wide range of physiological functions through interactions with multiple receptors, and to date seven families of 5-HT receptors have been identified (5-HT1–5-HT7), some of which have several receptor subtypes. Six of the seven subtypes are G-protein–coupled receptors, whereas the 5-HT3 receptor is a ligand-gated cation channel (reviewed in Hoyer et al., 1994; Barnes and Sharp, 1999).

3.1. 5-HT1A receptors

The first major family – the 5-HT1 receptors – is linked to the inhibition of adenylate cyclase and mainly function as inhibitory presynaptic and postsynaptic receptors. Of this family, the role of the 5-HT1A subtype in depression (more specifically in the mechanism of action of antidepressants) is relatively well-established. 5-HT1A receptors are coupled to several intracellular signalling mechanism, of which two have received most attention, the negative coupling to adenylate cyclase and the opening of K+ channels (Barnes and Sharp, 1999; Raymond et al., 2001). 5-HT1A receptors are found in two main populations: 1) serotonin neurons of the midbrain raphe nuclei (as presynaptic autoreceptors); and 2) postsynaptic neurons mainly in the hippocampus, septum, amygdala and corticolimbic areas (Sanabria-Bohorquez et al., 2002; Pazos and Palacios, 1985; Pompeiano et al., 1992; Martinez et al., 2001; Santana et al., 2004). As mentioned above, 5-HT1A receptors play an important role in the
self-regulation of the serotonergic system. Serotonergic activation of these receptors leads to opening of potassium channels in the cell membrane and hyperpolarisation of the cell, which results in a reduction in the discharge rate (Sprouse and Aghajanian, 1987; Sprouse and Aghajanian, 1986). Given the remarkable role of the neuronal discharge on the overall activity of the whole serotonergic system, the reduction in firing rate evoked by 5-HT₁A agonists translates immediately into a widespread reduction of 5-HT release in most brain areas, yet with a preferential effect on dorsal raphe-innervated regions (Hjorth and Sharp, 1991; Adell et al., 1993; Casanovas and Artigas, 1996; Casanovas et al., 1997).

Activation of 5-HT₁A autoreceptors by endogenous 5-HT plays a fundamental role in the physiological control of the activity of ascending 5-HT neurons. During waking periods, 5-HT neurons show a slow and regular discharge rate (pacemaker activity) (Jacobs and Azmitia, 1992). Under conditions of excessive excitatory input, such as those produced by stress, an increased 5-HT release occurs in the vicinity of cell bodies that activates inhibitory 5-HT₁A autoreceptors and helps to keep 5-HT neuronal firing low and regular (Adell et al., 1997; Celada et al., 2001; Martin-Ruiz and Ugedo, 2001). Thus, 5-HT₁A autoreceptors act as physiological ‘safety valves’ that help to maintain the homeostasis of the system. This physiological negative feedback mechanism plays a detrimental role in the mechanism of action of antidepressant drugs. Hence, the acute administration of antidepressants (tricyclic drugs, monoamine oxidase inhibitors and SSRIs) produces a very large increase of extracellular 5-HT in the midbrain raphe (Adell and Artigas, 1991; Bel and Artigas, 1992; Celada and Artigas, 1993), which activates 5-HT₁A receptors and so reduces 5-HT cell firing (Blier and de Montigny, 1994) and terminal 5-HT release (Romero et al., 1996; Artigas et al., 1996) (Fig. 1). Importantly, the effectiveness of this negative feedback pathway in inhibiting the effects of SSRIs clearly declines with prolonged treatment and is likely to result from the serotonin-induced desensitisation of raphe 5-HT₁A autoreceptors (Blier and de Montigny, 1994; El Mansari et al., 2005; Hervas et al., 2001), which
allows extracellular 5-HT to increase markedly more than after single administration (Bel and Artigas, 1993; Ferrer and Artigas, 1994; Hervas et al., 2001). It is thought that this feedback loop probably explains much of the slow and delayed clinical action of antidepressant drugs (Artigas et al., 1996; Artigas et al., 2001).

5-HT₁A receptor abnormalities have been reported in patients with MDD. Hence, postmortem and neuroimaging studies suggest an increased density of 5-HT₁A autoreceptors in major depressives compared with control subjects (Stockmeier et al., 1998; Parsey et al., 2006; Boldrini et al., 2008). Likewise, genetic studies have shown that individuals with elevated density or activity of 5-HT₁A autoreceptors are more susceptible to mood disorders and respond poorly to antidepressants (Lemonde et al., 2003; Neff et al., 2009). However, postsynaptic 5-HT₁A receptors have been shown to be unaltered or reduced in depressed patients, and this alteration is not sensitive to antidepressant treatment (Bhagwagar et al., 2004).

In the 1990s, I proposed that “5-HT₁A receptor antagonists could accelerate (and perhaps augment) the clinical effects of antidepressants by preventing this negative feedback” (Artigas, 1993) and showed that combining SSRI treatment with the mixed 5-HT₁A/β-adrenoceptor antagonist pindolol (the only potential 5-HT₁A antagonist available for human use by that time) markedly reduced the latency of the antidepressant response and increased the clinical response in previously untreated patients with MDD (Artigas et al., 1994; Artigas et al., 2006; see metanalyses in Whale et al., 2010; Ballesteros and Callado, 2004). However, pindolol addition was ineffective in treatment-resistant depressed patients (Perez et al., 1999), and the scarcity of 5-HT₁A receptor antagonists available for human use has limited the use of the ‘pindolol strategy’ to accelerate/enhance the antidepressant effects of SSRI. Since then, it has been of considerable interest to evaluate potential antidepressants that incorporate an action at 5-HT₁A receptors into their mechanism of action. To the best of my knowledge, two new
antidepressants [vilazodone, approved in 2011; and vortioxetine (Lu AA21004), in development] inhibit 5-HT reuptake and show partial agonism at 5-HT$_{1A}$ receptors (Page et al., 2002; Mork et al., 2012). Another drug (VN-2222; Romero et al., 2003), similar to vilazodone, was not developed due to industrial problems.

As well as improving the onset of action of SSRIs, 5-HT$_{1A}$ agents are known to exert their own, potentially therapeutic, actions. 5-HT$_{1A}$ ligands with partial agonist activity seem to possess antianxiety (Schreiber and De Vry, 1993), antidepressant (Robinson et al., 1990), antiaggressive (Sanchez and Hyttel, 1994, de Boer and Koolhaas, 2005), and perhaps anticraving (Naranjo and Bremner, 1993) and anticitatpelic (Prinssen et al., 2002) properties. Further, transgenic mice with a reduced expression of presynaptic 5-HT$_{1A}$ receptors (Richardson-Jones et al., 2010) and wild-type mice with siRNA-mediated suppression of 5-HT$_{1A}$ autoreceptors have been reported to display antidepressant-like behaviour (Bortolozzi et al., 2012).

It has been noted that prolonged antidepressant treatments result in a tonic activation of 5-HT$_{1A}$ receptors in the dorsal hippocampus (CA3 region) (Haddjeri et al., 1998) and that activation of 5-HT$_{1A}$ receptors in the dentate gyrus increases hippocampal neurogenesis (Jacobs et al., 2000). These observations, together with the antidepressant properties of 5-HT$_{1A}$ agonists in preclinical tests (see Cryan et al., 2005 for review), have led to the suggestion of 5-HT$_{1A}$ agonists as a new class of antidepressants (Blier and Ward, 2003). However, although some agents of this kind (e.g. buspirone, gepirone) show antidepressant efficacy in placebo-controlled trials, their efficacy appears to be lower than that of SSRIs, and these drugs have not succeeded in the antidepressant market. Two main reasons may account for the clinical failure of 5-HT$_{1A}$ agonists. Firstly, most agents of this kind (especially the azapirones) show preferential activation of presynaptic 5-HT$_{1A}$ receptors. This reduces 5-HT cell firing and terminal 5-HT
release. Second, with few exceptions, these agents tend to show a reduced efficacy at postsynaptic 5-HT₁A receptors. Thus, acute treatment with 5-HT₁A receptors replaces the endogenous transmitter (5-HT, with a 100% efficacy) from postsynaptic sites by the partial agonist, with a lower efficacy than 5-HT. This results in a paradoxical reduction of the tone at postsynaptic 5-HT₁A receptors. Higher doses (as those used in experimental animals) likely result in a greater activation of postsynaptic 5-HT₁A receptors, which may explain the positive results in animal tests. The importance of activating postsynaptic 5-HT₁A receptors for full antidepressant efficacy has been highlighted by a recent study showing that addition of the selective 5-HT₁A receptor antagonist DU125530 to fluoxetine treatment did not accelerate nor enhance the efficacy of fluoxetine in a randomised, placebo-controlled, double-blind clinical trial. DU125530 has equal potency and occupancy of pre- and postsynaptic 5-HT₁A receptors (Rabiner et al., 2002), and it is suggested that the blockade of postsynaptic 5-HT₁A receptors cancelled the benefits obtained by enhancing presynaptic serotonergic function (Scorza et al., 2011).

Unlike azapirones and other first-generation 5-HT₁A agonists, recently developed agonists hold promise to overcome these problems. For example, F15599 shows eightfold selectivity for postsynaptic 5-HT₁A receptors in hippocampus vs. raphe 5-HT₁A autoreceptors (Llado-Pelfort et al., 2010). Consistent with this preferential activation of postsynaptic 5-HT₁A receptors, this agent shows superiority vs. classical 5-HT₁A agonists in cognitive tests (Depoortere et al., 2010).

3.2. 5-HT₁B receptors

Like the 5-HT₁A receptor, 5-HT₁B receptors are located pre- and postsynaptically and negatively coupled to adenylate cyclase. Yet unlike 5-HT₁A autoreceptors, which are located in somatodendritically on 5-HT neurons, 5-HT₁B autoreceptors are located on serotonergic axons,
where they locally regulate 5-HT synthesis and release. Postsynaptic 5-HT\textsubscript{1B} receptors (or heteroreceptors) are predominantly located in motor control centres such as the basal ganglia, where they control synaptic transmission (Castro et al., 1998; Sari, 2004). Evidence implicating 5-HT\textsubscript{1B} receptors in the pathophysiology of depression comes from a number of converging lines of research. Two common genetic polymorphisms of 5-HT\textsubscript{1B} receptors, G861C (Huang et al., 2003) and C129T (Ruf and Bhagwagar, 2009), have been implicated in MDD and affective disorders. 5-HT\textsubscript{1B} receptor antagonists administered alone or with antidepressants have been shown to be effective in preclinical models of depression (Tatarczynska et al., 2004). On the other hand, the activation of 5-HT\textsubscript{1B} heteroceptors induces antidepressant-like behaviour (Chenu et al., 2008).

Recent interest has also focused on p11, an s100 EF-hand protein family protein that colocalizes with 5-HT\textsubscript{1B} and 5-HT\textsubscript{4} receptors (Egeland et al., 2011). P11 plays a central role in the modulation of 5-HT\textsubscript{1B} receptor function and is dysregulated in preclinical models of depression and postmortem MDD samples (Svenningsson et al., 2006). As with the 5-HT\textsubscript{1A} receptors, acute SSRI administration activates terminal 5-HT\textsubscript{1B} receptors, thus reducing 5-HT synthesis and release. Likewise, chronic administration of SSRI also results in desensitisation of terminal 5-HT\textsubscript{1B} autoreceptors (Neumaier et al., 1996), suggesting that plasticity in both the 5-HT\textsubscript{1A}– and 5-HT\textsubscript{1B}–mediated autoregulatory function may be important in the therapeutic profile of SSRI. As observed with 5-HT\textsubscript{1A} receptors, the administration of 5-HT\textsubscript{1B} receptor antagonists augments the neurochemical and behavioural effects of SSRIs (Gobert et al., 1997, 2000a; Rollema et al., 1996, Hervas et al., 2000). Interestingly, co-administration of the selective 5-HT\textsubscript{1A} antagonist WAY-100635 and the 5-HT\textsubscript{1B} receptor antagonist SB-224289 acts additively to potentiate the neurochemical actions of the SSRI, fluoxetine (Fig. 1). This has led to the suggestion that combining 5-HT\textsubscript{1A} and 5-HT\textsubscript{1B} receptor antagonism can elevate serotonin and therefore potentially be an effective strategy to treat depression.
3.3. Other 5-HT₁ receptors

Unlike the 5-HT₁A and 5-HT₁B receptors, the clinical significance of the other 5-HT₁-like (5-HT₁D, 5-HT₁E, 5-HT₁F) receptors remain less clear – although there is limited preclinical evidence linking some of these receptors to depression and associated conditions. Studies show that patients with depression have impaired sensitivity of the postsynaptic 5-HT₁D receptors (Whale et al., 2001). Similarly, another postmortem study of antidepressant-free suicide victims with a confirmed history of depression found a significantly higher density of 5-HT₁D receptors in the globus pallidus (Lowther et al., 1997). The 5-HT₁E receptor is highly expressed in the human frontal cortex and hippocampus, and it has been suggested that this distribution implies that 5-HT₁E receptors might be linked to cognition and memory (Klein et al., 2011).

3.4. 5-HT₂A receptors

5-HT₂A receptors, like the other members of the 5-HT₂ receptor family, are preferentially coupled to Gq/11 to increase inositol phosphates and cytosolic [Ca²⁺]. They are widely distributed at varying densities throughout the brain, with the highest density in the neocortex (Burnet et al., 1995). There is generally a close overlap between the distribution of 5-HT₂A mRNA and immunoreactivity, suggesting a postsynaptic location (Lopez-Gimenez et al., 2001b). In the cortex, 5-HT₂A receptors have been shown to be localised on GABAergic interneurons as well as glutamatergic projection neurons in human and rodent brain (Santana et al., 2004; de Almeida and Mengod, 2007).

Numerous antidepressants and antipsychotic agents bind with relatively high affinity at 5-HT₂A receptors. Although there is no direct correlation between their receptor affinities and clinically effective doses, cumulative evidence indicates that the 5-HT₂A receptor plays a role in depression. Several clinical studies have shown that atypical antipsychotic drugs (Carvalho et
al., 2008) and the antidepressant mirtazapine with affinity for α2-adrenoceptors and 5-HT2A receptors (Carpenter et al., 1999) augment the clinical response to SSRIs in treatment-resistant patients (Shelton et al., 2001). One common feature of these agents is their ability to occupy 5-HT2 receptors in the brain at clinical doses and more specifically to block 5-HT2A-mediated responses (Marek et al., 2003). Given the large co-expression of 5-HT1A and 5-HT2A receptors in the neocortex (Amargos-Bosch et al., 2004), blockade of 5-HT2A receptors might enhance the 5-HT1A receptor-mediated neurotransmission in cortical and limbic areas, an effect likely linked to the antidepressant efficacy (Fig. 2). Interestingly, the ventral parts of the anterior cingulate contain a higher proportion of 5-HT1A than of 5-HT2A receptors in the rodent (Santana et al., 2004) and human brains (Palomero-Gallagher et al., 2009), suggesting that SSRIs may preferentially inhibit neuronal activity in this region compared to more dorsal cingulate areas. This is an interesting observation, given the role of the subcallosal cingulate (mainly Broadman area 25) in the improvement of treatment-resistant depressive patients by deep brain stimulation (Mayberg et al., 2005; Kennedy et al., 2011; Puigdemonet et al., 2012).

Also, chronic administration of 5-HT2A antagonists has been reported to result in a paradoxical down-regulation of 5-HT2A receptors (Gray and Roth, 2001), which is predicted to be of benefit in the treatment of depression. Further, preclinical studies indicate that 5-HT2A antagonists possess anxiolytic properties, and the 5-HT2A antagonist ritanserin has been shown to have an antianxiety effect in humans (Bressa et al., 1987).

3.5. 5-HT2B receptors

The 5-HT2B receptor is largely expressed in peripheral tissues and has a restricted distribution in mammalian brain (Kursar et al., 1994; Bonhaus et al., 1995; Duxon et al., 1997). Interestingly, the 5-HT2B receptor mRNA is found in the dorsal raphe nucleus, suggesting a potential autoreceptor role (Bonaventure et al., 2002). 5-HT2B receptors mediate the well-known
contraction of rat fundus induced by 5-HT and appear to be involved in heart development (Nebigil et al., 2000). However, despite the limited knowledge regarding 5-HT2B receptor function in CNS, a recent study indicates its involvement in SSRI-mediated actions, showing also antidepressant-like properties of selective 5-HT2B receptor agonists (Diaz et al. 2012). The same study reports on the presence of 5-HT2B receptors in dorsal raphe 5-HT neurons and their stimulatory role on 5-HT release. However, given the role of 5-HT2B receptors in the peripheral actions of 5-HT, potential new antidepressants targeting 5-HT2B receptors may have important pulmonary and cardiovascular side effects.

3.6. 5-HT2C receptors

5-HT2C receptors are predominantly located in the choroids plexus, cerebral cortex, hippocampus, substantia nigra and cerebellum (Abramowski et al., 1995) and, like the 5-HT2A receptor, have been implicated in many processes, including mood, motor behaviour and appetite (Millan, 2005). Likewise, alterations in their functional status have been detected in anxiodepressive states (Niswender et al., 2001; Wood, 2003), and 5-HT2C sites are known to be involved in the actions of several classes of antidepressant drugs.

Although 5-HT2C receptors usually have a somatodendritic location, they may also be located on axon terminals in certain areas such as the septum and interpeduncular nucleus (presence of binding sites without mRNA expression) (Lopez-Gimenez et al., 2001a). Of interest, the localisation of 5-HT2C receptors in relation to serotonergic and GABAergic neurons has been studied in the anterior raphe nuclei. Such studies have found that 5-HT2C receptors are preferentially located on GABAergic interneurons (and not on serotonergic neurons), thereby supporting the idea that excitation of GABAergic interneurons through these 5-HT2C receptors is important in the suppression of serotonergic cell firing in the dorsal raphe and surrounding areas (Serrats et al., 2005). Likewise, 5-HT2C receptor immunoreactivity has been reported in
GABAergic cells of the prefrontal cortex (Liu et al., 2007) and in dopamine and GABA neurons of the mesolimbic pathway (Bubar et al., 2011).

An altered editing of the mRNA encoding 5-HT$_{2C}$ receptors has been reported in the prefrontal cortex of depressed suicide victims (Gurevich et al., 2002), suggesting an abnormal function of the receptor protein. Desensitisation of 5-HT$_{2C}$ receptors is also reported following chronic SSRI treatment. Preclinical data show that 5-HT$_{2C}$ antagonism augments the neurochemical and behavioural effects of SSRIs. For example, preclinical studies have shown that selective and nonselective 5-HT$_{2C}$ antagonists, potentiate the neurochemical effects of SSRIs on hippocampal and cortical extracellular 5-HT levels (Cremers et al., 2007; Cremers et al., 2004) and produces marked augmentation of the antidepressant effects of SSRIs in behavioural models of depression (Cremers et al., 2004). Despite the robust neurochemical effects when these agents are combined, 5-HT$_{2C}$ receptor antagonism alone has no significant effects on extracellular serotonin (Cremers et al., 2004). In contrast, various 5-HT$_{2C}$ receptor agonists were active in the forced swim test, suggesting antidepressant efficacy (Cryan and Lucki, 2000).

Additionally, 5-HT$_{2C}$ receptors are involved in the tonic modulation of dopaminergic activity (Gobert et al., 2000b; Invernizzi et al., 2007). The role of the meslimbic/mesocrotical DA systems in schizophrenia together with the high affinity of atypical antipsychoitc drugs 5-HT$_{2C}$ receptors has prompted the interest in this receptor (Meltzer et al., 2003). However, the modulation of the ascending dopaminergic activity may be also of interest in antidepressant drug development. Hence, 5-HT$_{2C}$ receptors have been reported to be involved in antidepressant-like effects in the forced swim test (Clenet et al., 2001).
3.7. 5-HT₃ receptors

The 5-HT₃ receptor is unique among all monoamine receptors in that it directly gates an ion channel—inducing rapid depolarisation that, in turn, causes the release of neurotransmitters and/or peptides. It is found throughout the brain and CNS and is in relatively high concentrations in the spinal cord and brainstem (area postrema), where it regulates vomiting. A number of 5-HT₃ receptor antagonists have been developed as antiemetics to be used with cancer chemotherapy. An antidepressant drug (litoxetine) was developed in the 1990s, combining SERT inhibition and 5-HT₃ antagonism to prevent SSRI-induced gastrointestinal side effects (Angel et al., 1993).

Within the forebrain, 5-HT₃ receptors have been found in the entorhinal, frontal and cingulate cortices, hippocampus, and amygdala (Thompson and Lummis, 2006). Immunohistochemical studies indicate that there is a differential cellular localisation of postsynaptic 5-HT₃ receptors within different central regions, depending on the nature of the neurons containing 5-HT₃ receptors. For instance, 5-HT₃ receptor immunoreactivity was most abundant in postsynaptic dendrite sites in the hippocampus, but was primarily associated with presynaptic nerve endings in amygdala (Miquel et al., 2002).

Importantly, 5-HT₃ receptors control dopamine and acetylcholine release. Likewise, they control the GABAergic system and this interplay with other neurotransmitter systems (see below) is suggested to be a primary mechanism of effect for 5-HT₃ ligands. Thus, different types of GABAergic interneurons in forebrain express 5-HT₃ receptors (Morales and Bloom, 1997; Puig et al., 2004). The physiological excitation of 5-HT neurons excites cortical (and possibly hippocampal) GABAergic neurons (Puig et al., 2004), an effect that likely results in the inhibition of neighbouring excitatory neurons via GABAₐ and GABAₐ receptors. Limited preclinical
evidence also suggests that the 5-HT\textsubscript{3} receptor plays a role in a variety of psychological/psychiatric disorders; however, the use of 5-HT\textsubscript{3} receptor antagonists has met with little success. Nevertheless, there is accumulating evidence of interaction of antidepressant drugs with 5-HT\textsubscript{3} receptors. Thus, antidepressant drugs with different mechanism of action show affinity for 5-HT\textsubscript{3} receptors (Lucchelli et al., 1995) and behave as functional antagonists (Eisensamer et al., 2003). Likewise, chronic fluoxetine treatment desensitises 5-HT\textsubscript{3} receptors (Fan, 1994), and SERT knockout mice show enhanced 5-HT\textsubscript{3} receptor density compared with wild-type mice (Mossner et al., 2004). More recently, it has been shown that 5-HT\textsubscript{3} receptor blockade with ondansetron potentiates the increase in extracellular 5-HT produced by citalopram in rat forebrain (Mork et al., 2012) Unlike the augmenting properties of 5-HT\textsubscript{1A} and 5-HT\textsubscript{1B} receptor antagonists, involving presynaptic interactions at somatodendritic and terminal levels, this observation likely involves long loops from prefrontal cortex to midbrain serotonergic neurons (Fig. 3). Several reports also suggest a relationship between 5-HT\textsubscript{3} receptors and anxiolytic/antidepressant behaviour. For example, transgenic knockout mice with deletion of the 5-HT\textsubscript{3} receptor exhibit anxiolytic behaviour (Kelley et al., 2003), in agreement with the anxiolytic effects of 5-HT\textsubscript{3} receptor antagonists (Barnes et al., 1992).

The use of 5-HT\textsubscript{3} receptor antagonists have also been employed for the alleviation of substance abuse, a common comorbidity with most psychiatric disorders, including MDD (Ostacher, 2007). In this respect, 5-HT\textsubscript{3} receptor antagonists have been reported to be particularly effective at reducing ethanol and morphine self-administration (Costall et al., 1993, Engleman et al., 2008). It is also interesting to note that a variety of antipsychotic drugs are noncompetitive 5-HT\textsubscript{3} receptor antagonists, and it has been suggested that this functional antagonism may contribute to their antipsychotic efficacy (Rammes et al., 2004). In addition, 5-HT\textsubscript{3} antagonists abolish the emotion-potentiated startle effect in humans (Harmer et al., 2006) and reverse helpless behaviour in rats (Martin et al., 1992). Likewise, 5-HT\textsubscript{3} receptor agonism attenuates
antidepressant-like effects in the forced swim test in rats (Nakagawa et al., 1998) and a 5-HT₃ receptor antagonist reduced immobility in the forced swim test (Kos et al., 2006). In line with these observations, the 5-HT₃ receptor antagonist ondansetron showed antidepressant-like properties in the tail suspension and forced swim tests, augmenting also the effects of fluoxetine (Kos et al., 2006). Interestingly, the novel antidepressant drug vortioxetine [currently in development (Baldwin et al., 2011; Alvarez et al., 2012)] shows nanomolar affinity for several 5-HT receptors, including 5-HT₃ receptors (Mork et al., 2012), the clinical relevance of which deserves further exploration.

3.8. 5-HT₄ receptors

5-HT₄ receptors are located predominantly in the putamen, caudate nucleus, hippocampus, nucleus accumbens, globus pallidus and substantia nigra; and to a lesser extent in the neocortex, raphe and pontine nuclei and some areas of the thalamus (Varnas et al., 2003). Positron emission tomography (PET) scan studies show a somewhat more restricted regional distribution in human brain, with a high 5-HT₄ receptor density in the caudate-putamen and much lower densities in frontal cortex and hippocampus (Marner et al., 2010). These receptors appear to be involved in the expression of genes of synaptic plasticity (Vidal et al., 2011), a common action of antidepressant drugs (Pittenger and Duman, 2008). The 5-HT₄ receptor interacts with p11, a protein required for antidepressant effects mediated by 5-HT₁B and 5-HT₄ receptors (Warner-Schmidt et al., 2009). Moreover, 5-HT₄ knockout mice show an exaggerated inhibitory response of 5-HT neurons to the SSRI citalopram (Conductier et al., 2006), suggesting that 5-HT₄ receptors are involved in the maintenance of the firing activity of 5-HT neurons during SERT inhibition. Thus, as observed with 5-HT₁₆ and 5-HT₂₆ receptors (Celada et al., 2001; Martín-Ruiz et al., 2001a), 5-HT₄ receptors in prefrontal cortex control the firing rate of midbrain serotonergic neurons via descending inputs (Lucas et al., 2005) (Fig. 3). Moreover, 5-
HT₄ receptors mediate the synaptic transmission between the dentate gyrus and CA3 through the mossy fibre pathway. Interestingly, fluoxetine had a normalising effect on this pathway via 5-HT₄ receptor activation (Kobayashi et al., 2008).

Preclinical studies show that administration of the 5-HT₄ agonists RS 67333 and prucalopride reduces immobility in the forced swim test, thereby displaying the potential of the 5-HT₄ receptor as a target for new antidepressant treatments (Lucas et al., 2007). Moreover, these studies show that administration of these agonists modifies rat brain parameters considered to be key markers of antidepressant action – namely, desensitisation of 5-HT₁A autoreceptors, increased tonus on hippocampal postsynaptic 5-HT₁A receptors, and enhanced phosphorylation of the CREB protein and neurogenesis in the hippocampus. Importantly, these effects were already present after only 3 days’ treatment (Lucas et al., 2007), whereas they are usually observed only after 2- to 3-week treatments with SSRIs. It has been suggested that the more rapid response to 5-HT₄ agonism is probably the result of parallel rapid and sustained activation of 5-HT neuronal firing in the dorsal raphe nucleus (Duman, 2007). Increased 5-HT neuronal firing could also underlie the apparently greater efficacy of the 5-HT₄ agonists relative to SSRIs, as the effect of reuptake inhibition is dependent on basal rates of 5-HT cell firing. Since the raphe nuclei do not appear to express 5-HT₄ receptors, the ability of 5-HT₄ receptors to stimulate serotonergic firing appears to involve activation of receptors located on neurons in the prefrontal cortex (Lucas et al., 2005). Although the identity of the cells that express 5-HT₄ receptors and their connections with the serotonergic neurons of the dorsal raphe nucleus is not yet known, it is possible that they project to other regions that contribute to the antidepressant actions of 5-HT₄ agonists (Duman, 2007).
3.9. 5-HT$_6$ receptors

5-HT$_6$ receptors are postsynaptic receptors with the highest expression in the striatum, nucleus accumbens, olfactory tubercle, and cortex, with moderate density in the amygdala, hippocampus, hypothalamus, thalamus and cerebellum (Branchek and Blackburn, 2000). There is considerable evidence for this receptor subtype playing a role in learning and memory (Rosse and Schaffhauser, 2010), as well as centrally regulated feeding behaviour (Heal et al., 2008). Hence, 5-HT$_6$ receptors are considered new targets for cognitive enhancement (Mitchell et al., 2006). Several tricyclic antidepressant drugs, such as amitriptyline, and atypical antidepressants, such as mianserin, display nanomolar affinity and antagonist activity at the 5-HT$_6$ receptor (Monsma et al., 1993). This finding, together with the distribution of the receptor in limbic and cortical brain areas, has led to the suggestion that 5-HT$_6$ receptors play an important role in the pathogenesis and/or treatment of depression (Monsma et al., 1993).

Preclinical studies have shown that 5-HT$_6$ antagonists such as SB-399885 exert an antidepressant-like effect in the forced swim and tail suspension tests in rodents (rats and mice) (Wesolowska and Nikiforuk, 2007). Moreover, combining a subeffective dose of SB-399885 with ineffective doses of imipramine, desipramine, bupropion or moclobemide was shown to have an antidepressant effect in the forced swim test in rats (Wesolowska and Nikiforuk, 2008). This suggests that inhibition of the 5-HT$_6$ receptor synergistically potentiates the effect of clinically used antidepressants, and it is interesting to speculate whether combining a lower dose of an antidepressant with a 5-HT$_6$ receptor antagonist might accelerate the onset of action and minimize the side-effect profiles. Confusingly, other preclinical studies have indicated that 5-HT$_6$ agonists may also be useful in treating depression. For example, it has been suggested that 5-HT$_6$ receptor stimulation may be a mechanism initiating some of the biochemical and behavioural outcomes of antidepressants such as fluoxetine (Svenningsson et al., 2007). On the other hand, the 5-HT$_6$ receptor agonist LY-586713 increased hippocampal BDNF expression – a
cellular marker of antidepressant action – after single administration (de Foubert et al., 2007) whereas SSRIs require repeated administration to elicit the same effect (Pittenger and Duman, 2008). On the same line, the 5-HT₆ receptor agonist EMD 386088 produced antidepressant-like and anxiolytic effects after intra-hippocampal administration (Nikiforuk et al., 2011). Thus, it is uncertain whether antagonists or agonists of this receptor will best treat depression. Moreover, the exact mechanism of action of 5-HT₆ ligands to elicit antidepressant-like effects is unknown and may involve changes in other neurotransmitter systems (Dawson and Li, 2003; Wesolowska, 2007).

3.10. 5-HT₇ receptors

The 5-HT₇ receptor, as first cloned in 1993, is highly expressed in the thalamus, hypothalamus, hippocampus and cortex (Hedlund and Sutcliffe, 2004). Findings from immunolocalisation and autoradiography studies are generally consistent with the mRNA distribution pattern (Neumaier et al., 2001; Varnas et al., 2004), which suggests predominant somatodendritic localisation. Since its discovery, a physiological role for 5-HT₇ receptors has been firmly established in the regulation of circadian rhythm, sleep, and mood (Hedlund, 2009).

As with the 5-HT₆ receptors, it was quickly noticed that several antidepressants (Monsma et al., 1993, Mullins et al., 1999) and antipsychotics (Roth et al., 1994) have high affinity for the 5-HT₇ receptor, leading to much subsequent research in its antidepressant effects. One preclinical study in the rat showed that several antidepressants, both tricyclics and SSRIs, induce c-fos expression in a way consistent with 5-HT₇ receptor activation within the suprachiasmatic nucleus, and that chronic antidepressant drug treatment leads to a down-regulation of 5-HT₇ receptor binding (Mullins et al., 1999). Preclinical studies also show an antidepressant-like and anxiolytic effect of the 5-HT₇ receptor antagonist SB 269970 in rodents (Wesolowska et al., 2006) as well as a synergistic interaction between subefficacious doses of this agent and
antidepressants, leading to reduced immobility in both the forced swim test and the tail suspension test (Bonaventure et al., 2007; Wesolowska et al., 2007). In addition, the genetic and pharmacological inactivation of 5-HT7 receptors partly reversed phencyclidine-induced deficits of pre-pulse inhibition, an animal model of antipsychotic activity (Semenova et al., 2008). In this respect, it should also be noted that the atypical antipsychotic aripiprazole, which has high affinity for the 5-HT7 receptor is sometimes used to augment the effect of traditional antidepressants (Berman et al., 2009). Similarly, a recent study has suggested that the antidepressant effects of amisulpride are due to its action at 5-HT7 receptors (Abbas et al., 2009). Overall, the 5-HT7 receptor is now being considered a new promising target in antidepressant drug development (Stahl, 2010).

4. Conclusions and implications for drug development

Despite new advances in the antidepressant field implicating glutamatergic mechanisms (Zarate et al., 2006), it is likely that the development of new antidepressant drugs in upcoming years will still be based on the monoamine systems. In particular, the serotonergic system is closely involved in the aetiology of depression and provides a rich opportunity for developing compounds with multiple and complementary modes of action. The literature review indicates that: 1) Presynaptic 5-HT1A and 5-HT1B autoreceptors play a major detrimental role in antidepressant treatments, whereas the stimulation of postsynaptic 5-HT1A receptors in corticolimbic networks is beneficial for the antidepressant action; 2) Blockade of 5-HT2A/2C receptors improves the actions of SSRIs, whereas 5-HT2B receptor activation enhances serotonergic activity and shows antidepressant-like activity in rodents (yet this observation requires further confirmation); 3) 5-HT3 receptor blockade can augment the antidepressant action of SERT inhibition; 4) 5-HT4 receptor activation appears to have antidepressant effects on its own and may augment SSRI effects; and 5) Blockade of 5-HT6 and 5-HT7 receptors may also improve the antidepressant effects of SERT inhibition.
Given the network, cellular and neurochemical complexity of the 5-HT system, its possible redundancies in terms of signalling pathways and the sometimes opposite role of some pre- and postsynaptic receptors (e.g. 5-HT₁₅), it seems clear that drugs acting on a single receptor are unlikely to overcome the limitations of SSRIs, although new molecular approaches with cellular specificity, such as siRNA strategies, may perhaps overcome the limitations of drugs, which often do not discriminate between the same receptors expressed in different cellular phenotypes or brain regions. Therefore, it is likely that future antidepressant drugs overcoming the limitations of SSRIs and SNRIs will be developed on the basis of SERT inhibition (and perhaps NET inhibition) plus additional pharmacological activities at pre- and/or postsynaptic receptors. On the one hand, these activities should prevent the several 5-HT cell-based and network-based negative feedback mechanisms that limit presynaptic serotonergic activity. This may include the selective reduction of 5-HT₁₅ and/or 5-HT₁₈ autoreceptor function plus the blockade of some postsynaptic receptors present in GABAergic neurons (5-HT₃ and perhaps others) involved in the local and distal inhibition of serotonergic activity. On the other hand, since postsynaptic receptors play different and often opposing roles in experimental tests of depression, new compounds should show different postsynaptic activities, being agonists at certain receptors, such as 5-HT₁₅ (yet with the aforementioned problem of suppressing presynaptic 5-HT activity) and 5-HT₄ receptors and antagonists at other excitatory 5-HT receptors (e.g. 5-HT₂₁₂/₂₁₅, 5-HT₆, 5-HT₇). Indeed, drugs showing all these pharmacological activities are technically unfeasible and might present many side effects due to their large number of pharmacological activities. However, it should be noted that recently developed compounds such as vilazodone and vortioxetine (Lu AA21004) go along these lines, as they add a partial 5-HT₁₅ agonist activity to SERT inhibition, mimicking the pharmacological actions of the SSRI + pindolol combination (vortioxetine shows additional activities at other 5-HT
receptors; see above). Future drugs may incorporate new activities in parallel with a better knowledge of the 5-HT system.

The antidepressant properties of 5-HT–enhancing drugs and of agonists/antagonists of 5-HT receptors derive from their modulation of corticolimbic networks whose function is altered in major depression, thereby normalising neurotransmitter function (glutamate, GABA) in these circuits. This effect may also be evoked by other monoamines, such as NE and DA, whose transporters are targeted by other antidepressant drugs (acetylcholine may also participate by improving cognitive symptoms). 5-HT exerts a widespread and complex regulation of the function of monoaminergic neurotransmission (Fink and Gothert, 2007) which is often reciprocal (e.g. serotonergic activity is tonically dependent on an α₁-adrenergic input). As an example, activation of 5-HT₁A receptors increases the release of NE and DA in forebrain, an effect likely involving 5-HT₁A receptors in cortical pyramidal neurons projecting to the brainstem (HajosKorcsok and Sharp, 1996; Díaz-Mataix et al., 2005). On the other hand, 5-HT₃ receptor blockade stimulates acetylcholine release (Barnes et al., 1989). Thus, changes in serotonergic activity evoke a series of parallel changes of these other monoamines, which may also contribute to the clinical action of antidepressant drugs acting primarily on the 5-HT system.

Novel molecular mechanisms have been identified in the last decade that affect neurotransmitter function. Hence, microRNA are related to the pathophysiology and treatment of several CNS diseases, including depression (Mouillet-Richard et al., 2012), being also involved in the regulation of serotonergic neurotransmission (Millan et al., 2011). In particular, microRNA-16 has been shown to modulate SERT expression and to be modulated by chronic antidepressant treatments (Baudry et al., 2010) and mediates the enhancement of hippocampal neurogenesis by SSRI (Launay et al., 2011). Moreover, small interference RNA (siRNA) has been used to modulate the expression of serotonergic genes and to evoke antidepressant-like
effects in rodents. Hence, the reduction of the expression of SERT increased serotonergic function and reduced the immobility in the forced-swim test (Thakker et al., 2005). Likewise, the selective reduction of 5-HT$_{1A}$ autoreceptor expression by a modified siRNA selectively targeting raphe 5-HT neurons (Bortolozzi et al., 2012) or by the local application of unmodified siRNA into the dorsal raphe (Ferrés-Coy et al., 2012) enhanced serotonergic function and evoked strong antidepressant-like effects. Overall, the use of these molecular strategies may add to pharmacological approaches in the search for new antidepressant treatments overcoming the limitations of existing drugs.

In conclusion, the 5-HT system offers a large number of possibilities to develop new antidepressant treatments, based on combinations of different pharmacological activities in addition to SERT inhibition. Yet, these activities need to be carefully selected to overcome self-limiting mechanisms of serotonergic activity as well as a selective activation or blockade of relevant postsynaptic receptors. In addition to drugs, new therapeutic approaches based on molecular approaches achieving cellular specificity may be possible.

**Acknowledgements**

Supported by the Innovative Medicine Initiative Joint Undertaking under grant agreement n° 115008, of which resources are composed of EFPIA in-kind contribution and financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and by grant SAF 2012- 35183 from the Ministerio de Economía y Competitividad. Support from the Generalitat de Catalunya (2009-SGR220) and the Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) is also acknowledged.
Conflict of interest

FA has received consulting and educational honoraria on antidepressant drugs from Eli Lilly and Lundbeck A/S. FA has also been PI from a research contract with Pierre Fabre on 5-HT$_{1A}$ agonists and with nLife Therapeutics on siRNA modulation of serotonergic function.
References


79. GOBERT, A., DEKEYNE, A. & MILLAN, M. J. 2000a. The ability of WAY100,635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224,289, but not BRL15572. *Neuropharmacology*, 39, 1608-16.


159. PUIGDEMONT, D., R. PEREZ-EGEA, M. J. PORTELLA, J. MOLET, J. DIEGO-adelino, A. GIRONELL, J. RADUA, B. GOMEZ-ANSON, R. RODRIGUEZ, M. SERRA,


Box 1. Main characteristics of the serotonergic system in mammalian brain

- Low number of neurons: 250,000 5-HT neurons in the human brain (out of a total of $10^{11}$)
- Extensive arborisation (>10⁶ nerve terminals/mm³)
- Innervation of the whole neuraxis
- Control of activity by descending (prefrontal cortex, lateral habenula, hypothalamus, etc.) and ascending (locus coeruleus, spinal cord) inputs to the raphe nuclei
- Slow and regular discharge (pacemaker neurons): strong homeostasis
- Neuronal activity dependent on sleep-wake cycles (REM-off neurons)
- Very sensitive to self-inhibition through activation of 5-HT₁₅ autoreceptors
- Rich neurochemistry: 14 different postsynaptic receptors
- Implication in a large number of physiological functions
- Mutual control with monoaminergic cell groups
Fig. 1. Role of 5-HT$_{1A/1B}$ autoreceptors in the mechanism of action of antidepressant drugs. A) Serotonin-enhancing drugs, such as the selective serotonin reuptake inhibitors (SSRIs) and the serotonin and norepinephrine reuptake inhibitors (SNRIs), exert two opposite actions on the active (extracellular) fraction of 5-HT in forebrain. On the one hand, SERT inhibition in forebrain nerve terminals increases the extracellular 5-HT concentration in corticolimbic areas. On the other hand, the excess 5-HT evoked by inhibition of SERT (maximal density in the raphe nuclei due to the presence of a dense network of 5-HT fibres (see B) activates raphe 5-HT$_{1A}$ autoreceptors, thus reducing serotoninergic cell firing and impulse-dependent 5-HT release by forebrain axons. An additional negative feedback mechanism is exerted by the activation of 5-HT$_{1B}$ autoreceptors in serotoninergic nerve terminals. 5-HT autoreceptor desensitisation after
repeated treatment reduces the efficacy of negative feedback mechanisms and allows the active 5-HT concentration to increase several-fold. B) Increase in extracellular concentration produced by the SSRI fluoxetine (FLX, 1, 3 and 10 mg/kg) in six different regions of the rat brain. Note the large effect of SERT blockade by fluoxetine in the dorsal and median raphe nuclei at all doses in parallel with a moderate (if any) effect in forebrain regions. The effect of low doses is particularly relevant for clinical effects in depressed patients (20 mg/day for an average weight of 70 kg, i.e. 0.3 mg/kg·day in humans). C) The combined administration of the selective antagonists of 5-HT$_{1A}$ and 5-HT$_{1B}$ receptors (WAY-100635, 0.3 mg/kg s.c. and SB224289, 4 mg/kg i.p., respectively) augmented the effect of the SSRI fluoxetine (10 mg/kg i.p.) on extracellular 5-HT concentration in rat prefrontal cortex, mimicking the effects of autoreceptor desensitisation. D) Similarly, the knockdown of 5-HTH$_{1A}$ autoreceptors induced by a conjugated siRNA directed towards 5-HT$_{1A}$ autoreceptors (C-1A-siRNA) augmented the effect of fluoxetine (20 mg/kg i.p.) on extracellular 5-HT in mouse prefrontal cortex up to the level seen in constitutive 5-HT$_{1A}$ knockout mice (1A-KO). Note the small effect of fluoxetine in two groups of control mice (pre-treated with vehicle and nonsense siRNA –C-ms-siRNA, respectively). Results are means ± SEM values of extracellular 5-HT in the various experimental groups. Redrawn from data in Hervás and Artigas (1998), Hervás et al. (2000), and Bortolozzi et al. (2012). Abbreviations: DR, dorsal raphe nucleus; DHPC, dorsal hippocampus; MnR, median raphe nucleus; PFC, prefrontal cortex; STR, dorsal striatum; VHPC, ventral hippocampus. Panel A redrawn from Artigas et al. (2001) with permission.
Fig. 2. Schematic representation of the putative antidepressant mechanism of 5-HT_{2A} receptor blockade. A) Low magnification image from the prelimbic area of the medial prefrontal cortex (mPFC) showing the presence of cells expressing 5-HT_{1A} (left panel) and 5-HT_{2A} receptor mRNA (right panel) labeled by double in situ hybridization using nonradioactive (digoxygenin, left) and radioactive (^{33}P, right) oligonucleotides. Note the abundance of cells expressing one or other receptor, particularly in layers II-V. B) High-resolution image from the same area showing individual cells expressing both receptor transcripts, as denoted by the simultaneous presence of background dark cellular profiles (5-HT_{1A}, digoxygenin-labeled) and black silver grains (5-
HT$_{2A}$, $^{33}$P-labeled). C) Upper panel. The excess 5-HT produced by SERT inhibition in prefrontal cortex (PFC) activates excitatory 5-HT$_{2A}$ and inhibitory 5-HT$_{1A}$ receptors in pyramidal neurons projecting to other cortical as well as subcortical areas, including the limbic system. Lower panel. Due to the large coexpression of 5-HT$_{2A}$ and 5-HT$_{1A}$ receptors in PFC neurons (ca. 80%; Amargós-Bosch et al., 2004; see B), the blockade of 5-HT$_{2A}$ receptors enhances 5-HT$_{1A}$ receptor-mediated neurotransmission, thus changing the top-down control of PFC on corticolimbic networks. Panels A and B taken from Amargós-Bosch et al. (2004) with permission.
Fig. 3. Schematic representation of the functional connectivity between the medial prefrontal cortex (mPFC) and the dorsal and median raphe nuclei (DR(MnR), in relationship to the putative antidepressant mechanism of 5-HT₃ receptor blockade. The activity of pyramidal neurons in PFC is controlled by a balance between excitatory inputs (AMPA, NMDA) from other cortical areas, the thalamus, the hippocampus and the amygdala, and inhibitory inputs (mainly GABAₐ, GABAₐ₉ and mGluR II/III). Monoamines may play both excitatory and inhibitory roles, depending on the receptor activated. 5-HT₃ receptors are expressed by GABAergic interneurons in the hippocampal formation (Morales and Bloom, 1997) and the medial prefrontal cortex (mPFC; Puig et al., 2004). 5-HT₃ receptor-containing interneurons are located in upper cortical layers than those expressing 5-HT₂A receptors, indicating that 5-HT₃ receptors control excitatory inputs onto apical dendrites. 5-HT₃ receptors are excited by the physiological release of 5-HT, this
enhancing the local inhibitory tone via GABA$_A$ and GABA$_B$ receptor activation. 5-HT$_3$ receptor blockade may thus decrease local negative feedback on 5-HT release mediated by terminal GABA$_B$ heteroreceptors. Additionally, 5-HT$_3$ receptor blockade may decrease the GABA$_A$ receptor-mediated tone on mPFC neurons projecting to midbrain, thus enhancing the activity of the ascending brainstem monoaminergic systems (serotonergic neurons of the DR/MnR; dopaminergic neurons of the ventral tegmental area, VTA; noradrenergic neurons of the locus coeruleus, LC) that are under the excitatory control of the PFC (Gabbott et al., 2005). Both mechanisms may account for the augmentation of SSRI effects by the selective 5-HT$_3$ receptor antagonist ondansetron (Mork et al., 2012). Abbreviations: DR, dorsal raphe nucleus; LC, locus coeruleus; MnR, median raphe nucleus; VTA, ventral tegmental area.